Phase III success will help expand the CD19-targeting drug’s niche in lymphoma, as Incyte looks for growth beyond the coming expiry of its blockbuster Jakafi.
Incyte’s Monjuvi has recorded a Phase III trial success in follicular lymphoma, which should expand the CD19-targeting antibody’s use and help the company build its presence in oncology.
The mid-sized biopharma acquired full global rights to Monjuvi (tafasitamab) from former marketing partner MorphoSys in February for just $25m...
FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.
The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.
Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.
The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.
With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.
The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.
Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.
